Australia markets close in 3 hours 57 minutes

CryoLife, Inc. (CRY)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
20.87+0.83 (+4.14%)
At close: 4:00PM EST

20.87 0.00 (0.00%)
After hours: 4:19PM EST

CryoLife, Inc.

1655 Roberts Boulevard N.W.
Kennesaw, GA 30144
United States
770 419 3355
http://www.cryolife.com

Sector(s)Healthcare
IndustryMedical Devices
Full-time employees1,200

Key executives

NameTitlePayExercisedYear born
Mr. James Patrick MackinChairman, Pres & CEO1.33MN/A1967
Mr. David Ashley Lee CPA, CPAExec. VP, COO & CFO712.66k420.47k1965
Ms. Jean F. HollowaySr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.551.04k453.38k1957
Mr. John E. DavisSr. VP of Global Sales & Marketing514.88kN/A1965
Mr. Michael S. SimpsonSr. VP of Regulatory Affairs & Quality Assurance571.22kN/A1968
Ms. Amy D. Horton CPA, CPAVP & Chief Accounting OfficerN/AN/A1970
Mr. Matthew A. GetzVP of HRN/AN/A1969
Mr. Thomas J. BogenschützSr. VP of Europe, Middle East & AfricaN/AN/A1967
Joshua WellsSr. Director of Bus. Devel.N/AN/AN/A
Karen K. DabbsAssistant Corp. Sec.N/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products, a range of stent graft systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G, a stent graft system for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers vascular preservation services; synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products, such as YAG laser consoles, related service and maintenance, and single-use, fiber-optic handpieces; and CryoVein femoral vein and CryoArtery femoral artery vascular preservation services for vascular access. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

Corporate governance

CryoLife, Inc.’s ISS governance QualityScore as of 1 November 2019 is 2. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 3; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.